Open AccessAn inpatient human laboratory study assessing the safety and tolerability, pharmacokinetics, and biobehavioral effect of GET 73 when co-administered with alcohol in individuals with alcohol use disorder
Author(s) -
Carolina L. HaassKoffler,
Roberta Perciballi,
Molly Magill,
Antonella Loche,
Roberto Cacciaglia,
Lorenzo Leggio,
Robert M. Swift
Publication year - 2021
Publication title -
psychopharmacology/psychopharmacologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.378
H-Index - 196
eISSN - 1432-2072
pISSN - 0033-3158
DOI - 10.1007/s00213-021-06008-1
Subject(s) - tolerability , alcohol , pharmacokinetics , alcohol use disorder , psychiatry , psychology , alcohol and health , clinical psychology , medicine , pharmacology , alcohol consumption , adverse effect , biochemistry , chemistry
Previous work suggests that GET 73, a novel compound with putative activity on the metabotropic glutamate receptor subtype 5 (mGluR5), may represent a novel pharmacological treatment for alcohol use disorder (AUD).